Introduction
Ideas, recommendations, potential inclusion criteria, methods and limitations for clinical trials for 'pre-dementia,' 'prodromal,' or early Alzheimer's disease are discussed 1 . We wish to be able to study AD treatments before the onset of a dementia syndrome which is an essential criterion for the clinical diagnosis of NINCDS-ADRDA probable or possible AD (1).
Including patients with mild probable AD in clinical trials may be unsatisfactory because the disease process may be too advanced to detect substantial clinical benefit from treatment as is illustrated by the small clinical effects seen with the marketed cholinesterase inhibitors and memantine. Despite use of the adjective 'mild,' patients with mild AD have dementia and have been significantly impaired for about 2 to 4 years on average prior to diagnosis, if not longer.
Studying patients with mild cognitive impairment or amnestic MCI has been considered an unsatisfactory approach to AD clinical trials because most patients do not progress to dementia over the 1 to 4 year trial periods (2), and because of those that develop dementia about 30% do not meet neuropathological criteria for AD (3). Trials that include patients with amnestic MCI include unknown proportions of patients with and without AD or the neuropathology of AD.
Accurately identifying early AD will allow the testing of treatments that may be effective earlier in the illness when there are fewer signs and symptoms, and presumably less underlying neuropathological substrate, and that might have both greater immediate and continuing effects over the course of illness. Improving cognitive function during the pre-dementia phase of the illness might substantially improve health-related quality of life and mitigate the progression of illness when it may matter most. It is also possible to test treatments that might be effective at an early, pre-dementia stage of illness but not later on when there may be too much neuronal degeneration to overcome and loss of therapeutic drug targets.
One caveat in this discussion is that 'early' AD as described here means clinical signs and symptoms of AD before dementia but still might not mean early in the neuropathology of the illness. Effectively treating early AD should not be considered primary or secondary prevention, but rather 'tertiary' prevention or treatment of the symptoms and disease itself.
Thus, by definition, the ability to do clinical trials in early AD rests entirely on being able to accurately diagnose it. Part
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of the diagnostic process is the ability to accurately identify a person who does not have early AD, i.e., is normal, has MCI (and not early AD), has mild probable AD (not early AD), or has another cognitive-impairment syndrome such as one due to cerebrovascular disease. Complicating this effort is the lack of an ante mortem 'gold standard' for an AD diagnosis and lack of validated drug targets for therapeutic drug development. The clinical border between MCI and mild AD is not sharp. Although considered a risk or transitional state to AD (4), a proportion of patients diagnosed with MCI can be diagnosed as AD by their physicians. Thus many patients with MCI could be perceived to have mild AD and entered into AD trials; and a proportion of mild AD patients could be perceived to have MCI and entered into MCI trials. Specifically, AD trials that allow patients to enter with Mini-Mental State Examination (5) scores of 26 and below can include some patients with MCI; and MCI trials that allow patients to enter with MMSE scores of 24 and higher could include patients with mild AD.
A practical effect for MCI trials is to enrich a sample for the development of probable AD over a 2 to 4 year period (2). Consequently, a group of amnestic MCI patients likely includes the subset 'pre-dementia AD,' prodromal AD, or early AD. Moreover, some patients considered to have mild probable AD could also qualify for early AD using proposed research criteria, and early AD can include both MCI and mild AD within its criteria.
Criteria for MCI, early AD and probable AD
The following table displays differences and similarities among MCI, proposed research criteria for early AD, and probable AD by current research criteria.
The essential distinction between the proposed research criteria (when specifically applied to early AD) and either amnestic MCI or probable AD is the requirement for a biomarker as a supportive feature. Clearly early AD criteria occupy a position between MCI and mild AD criteria (1, 4, 6 ).
Enrichment and biomarkers
The current biomarkers under discussion (6) are state markers that can vary with illness, may not always be expressed, and may be influenced by factors other than disease progression. It has not been determined whether the biomarkers under consideration are necessary diagnostic markers that -along with other characteristics -can be used to make an accurate AD diagnosis or are biomarkers that serve to increase the likelihood for an AD diagnosis or enrich the study sample for the subsequent development of probable AD.
Early AD as it is formulated here could be considered a more advanced risk state for AD relative to amnestic MCI. An implication is that episodic memory impairment coupled with a biomarker increases the likelihood for AD to near the level as the current criteria for probable AD that requires the presence 
